Medicines labeled for the same conditions

Alternatives to cytarabine and daunorubicin

34 other medicines are given the same way (intravenous) and in the same FDA class as cytarabine and daunorubicin or labeled mainly for the same use (leukemia, lymphoma and myeloma); 6 are in its class, anthracycline topoisomerase inhibitors: doxorubicin, nelarabine, idarubicin, clofarabine and 2 more; the others include 4 alkylating drugs, 2 proteasome inhibitors and 2 cd20-directed cytolytic antibodies (FDA labels read October 8, 2026).

Which medicines are labeled for the same conditions as cytarabine and daunorubicin?

The first 24 of the 34, the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA class	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Boxed warning	Shortage
Cytarabine and daunorubicinanthracycline topoisomerase inhibitor	this medicine	none listed	n/a	Yes	No current entry
Doxorubicinanthracycline topoisomerase inhibitor · same class	Leukemia, lymphoma and myeloma	16 labelers	n/a	Yes	No current entry
Nelarabinenucleoside metabolic inhibitor · same class	Leukemia, lymphoma and myeloma	12 labelers	n/a	Yes	No current entry
Idarubicinanthracycline topoisomerase inhibitor · same class	Leukemia, lymphoma and myeloma	2 labelers	n/a	Yes	No current entry
Clofarabinenucleoside metabolic inhibitor · same class	Leukemia, lymphoma and myeloma	9 labelers	n/a	No	No current entry
Fludarabinenucleoside metabolic inhibitor · same class	Leukemia, lymphoma and myeloma	6 labelers	n/a	Yes	No current entry
Pentostatinnucleoside metabolic inhibitor · same class	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	In shortage
Cyclophosphamidealkylating drug	Leukemia, lymphoma and myeloma	15 labelers	n/a	No	No current entry
Bortezomibproteasome inhibitor	Leukemia, lymphoma and myeloma	22 labelers	n/a	No	No current entry
Arsenic trioxide	Leukemia, lymphoma and myeloma	16 labelers	n/a	Yes	A presentation being discontinued
Bendamustinealkylating drug	Leukemia, lymphoma and myeloma	4 labelers	n/a	No	A presentation being discontinued
Melphalanalkylating drug	Leukemia, lymphoma and myeloma	6 labelers	n/a	Yes	A presentation being discontinued
Rituximabcd20-directed cytolytic antibody	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Pralatrexatefolate analog metabolic inhibitor	Leukemia, lymphoma and myeloma	1 labeler	n/a	No	No current entry
Carmustinealkylating drug	Leukemia, lymphoma and myeloma	3 labelers	n/a	Yes	No current entry
Mitoxantronetopoisomerase inhibitor	Leukemia, lymphoma and myeloma	3 labelers	n/a	Yes	No current entry
Carfilzomibproteasome inhibitor	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Daratumumabcd38-directed cytolytic antibody	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Elotuzumabslamf7-directed immunostimulatory antibody	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Glofitamabbispecific cd20-directed cd3 t cell engager	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Isatuximabcd38-directed cytolytic antibody	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Mosunetuzumab	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Tafasitamab	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Belantamab mafodotin	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Belinostathistone deacetylase inhibitor	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Cytarabine and daunorubicin: the full record: label, generics, price, shortages, recalls